Promising Target Antigens for Cell Therapy of Solid Tumors
CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens, and have shown promising results in some trials. Sino Biological provides a comprehensive range of reagents and services to support the development of CAR-T therapies targeting solid tumors.
Featured Recombinant Proteins and Corresponding Antibodies
To support cell therapy research for solid tumors, Sino Biological provides high-quality target proteins covering FAP, GPC3, HER2, L1CAM, CEACAM5, MSLN, IL-13RA2, EpCAM, PSMA, EGFR, and more. These recombinant proteins have been validated for activity, and are trusted by users as indicated by citations in top-tier journals. The antibody products for these target antigens are also available, with a variety of applications, such as ELISA, IHC-P, FCM, IP, and WB.
Click for more cell therapy target proteins and corresponding antibodies.
More about Cell Therapy:
[Products] Cytokines for Cell Therapy Research
[Solutions] Comprehensive CAR-T Therapy Development Solutions
[Solutions] Research Solutions and Support for CAR-NK Therapy Development
[In Focus] CAR-T and CAR-NK Cell Therapies Research Resources
